A Phase Ib Neoadjuvant Study of the Gamma Secretase Inhibitor (RO4929097) in Combination With the Aromatase Inhibitor Letrozole in Post-Menopausal Women With Stage II/III Hormone Receptor-Positive Breast Cancer.
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2013
At a glance
- Drugs Letrozole (Primary) ; RG 4733 (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 01 Jul 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 14 Jan 2013 Planned end date changed from 1 Jan 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.